Review



fda approved compounds  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    TargetMol fda approved compounds
    Fda Approved Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 83 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved compounds/product/TargetMol
    Average 95 stars, based on 83 article reviews
    fda approved compounds - by Bioz Stars, 2026-04
    95/100 stars

    Images



    Similar Products

    93
    Bio-Techne corporation tocriscreen fda-approved drugs library
    Tocriscreen Fda Approved Drugs Library, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tocriscreen fda-approved drugs library/product/Bio-Techne corporation
    Average 93 stars, based on 1 article reviews
    tocriscreen fda-approved drugs library - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    95
    TargetMol fda approved compounds
    Fda Approved Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved compounds/product/TargetMol
    Average 95 stars, based on 1 article reviews
    fda approved compounds - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals fda approved drug library
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Fda Approved Drug Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved drug library/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    fda approved drug library - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    Selleck Chemicals fda approved drug screening library
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Fda Approved Drug Screening Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved drug screening library/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    fda approved drug screening library - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    Selleck Chemicals apexbio fda approved drug library
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Apexbio Fda Approved Drug Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apexbio fda approved drug library/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    apexbio fda approved drug library - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    94
    TargetMol pharmacopeia
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Pharmacopeia, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pharmacopeia/product/TargetMol
    Average 94 stars, based on 1 article reviews
    pharmacopeia - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    95
    Tocris tocriscreen library
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Tocriscreen Library, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tocriscreen library/product/Tocris
    Average 95 stars, based on 1 article reviews
    tocriscreen library - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals plate 1
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Plate 1, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plate 1/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    plate 1 - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    95
    Tocris compounds
    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated <t>with</t> <t>FDA-approved</t> drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h
    Compounds, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compounds/product/Tocris
    Average 95 stars, based on 1 article reviews
    compounds - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    Image Search Results


    Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated with FDA-approved drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Glucocorticoids elevate clear cell renal cell carcinoma sensitivity to HIF-2α inhibitors by suppressing H4K12 lactylation

    doi: 10.1038/s41392-026-02622-7

    Figure Lengend Snippet: Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated with FDA-approved drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h

    Article Snippet: The agents used were belzutifan and SO (MedChemExpress, MCE), DEX, DCA, sodium lactate, and the FDA-approved drug library (Selleck).

    Techniques: Drug discovery, Control, Immunofluorescence, Staining, High Content Screening, Fluorescence, Labeling, Western Blot